Cannabis Sector Sees Policy Wins and Sales Gains - Jan 24

The Big Picture

Policy and cash are leading the narrative for cannabis heading into the long weekend. Ohio has started distributing cannabis tax receipts to local governments, a direct signal that legalized markets are delivering budgetary benefits, and Arkansas reported record medical cannabis sales of $291 million in 2025.

Those developments, coupled with bipartisan legislative activity on CBD Medicare coverage and continuing debate over federal rescheduling, suggest the sector is getting incremental but meaningful support from both state and federal channels. You should pay attention to how lawmakers and local officials follow through, because that will shape market opportunities for companies and investors alike.

Market Highlights

Here are the top quick facts and movers from the cannabis beat you should know.

• Ohio revenue rollout: Cities and towns that allowed recreational dispensaries are now receiving funds generated by a 10 percent cannabis excise tax, a milestone after earlier delays.
• Arkansas sales record: Medical cannabis sales reached $291 million in 2025, surpassing the prior high of $283 million set in 2023 and exceeding 2024 totals by roughly $15 million.
• Federal policy headlines: A bipartisan bill would give the FDA authority over hemp and could advance CBD Medicare coverage, while legal experts continue to parse President Trump’s rescheduling directive focused on medical cannabis.
• Culture and consumer demand: Viral moments, like Wiz Khalifa smoking with Argentine star Duki at Sauce Boyz Fest, and creators such as Weedy Won K drawing large audiences, are keeping cannabis conversation in mainstream entertainment.
• Sector tickers to watch: Keep an eye on $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY for ETF and equity exposure as policy and state sales data continue to steer flows.

Key Developments

Ohio Begins Disbursing Cannabis Tax Revenue

State officials started sending the 10 percent cannabis tax receipts to local governments that host dispensaries. That follows earlier reports that nearly $11 million had been withheld; the release closes a transparency gap and sends immediate cash to municipal budgets.

For investors, the practical implication is twofold: first, local acceptance reduces political risk for existing operators, and second, recurring tax receipts create predictable demand signals for retailers and producers. How that money is spent could also create downstream opportunities in local services and infrastructure, so watch municipal budgets closely.

Federal Policy: CBD, Medicare, and Rescheduling Questions

Congressional sponsors introduced bipartisan language that would put federal hemp regulation under the FDA and could pave the way for CBD to be considered for Medicare coverage. At the same time, legal analysis of the president’s rescheduling order highlights ambiguity since the order emphasized medical cannabis.

These are incremental but important policy moves. If FDA oversight and Medicare coverage advance, you could see broader clinical acceptance and demand for regulated CBD products. But the timing and scope remain uncertain, so don’t assume immediate commercial change.

Sales Momentum and Cultural Mainstreaming

Arkansas’ $291 million medical market and viral cultural moments indicate both steady consumption and mainstream normalization. Celebrity visibility, from Wiz Khalifa sharing a moment with Duki to viral creators turning cannabis content into mass audiences, helps destigmatize use and can expand customer bases over time.

That cultural tailwind matters for brand building and retail foot traffic, but it won’t replace the need for disciplined distribution and regulatory compliance. Will mainstream attention translate to bigger market share for the leading operators? It could, if companies convert awareness into retail presence and product availability.

What to Watch

Here are the catalysts and risks you should track before markets reopen on Monday, Jan 26.

• Federal rulemaking and hearings: Monitor any FDA steps on hemp regulation and congressional activity on CBD Medicare coverage, both of which could reshape product categories and reimbursement dynamics.
• Rescheduling guidance: Legal clarifications about whether rescheduling targets medical cannabis only will affect banking, research access, and interstate commerce. Will regulators provide clarity or leave ambiguity? That question matters for valuations.
• State budget uses in Ohio: Watch how local officials allocate newly received cannabis revenue, you might find municipal contracts and local tax policies that benefit regional operators.
• Sales reports and quarterly filings: Expect companies and regional markets to report January and Q4 trends soon, and those numbers will tell you if Arkansas-style growth is replicable elsewhere.
• ETF flows and major tickers: Keep an eye on $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY for flows and news-driven moves once markets reopen, since policy headlines often trigger rapid repositioning.
• Reputation and marketing risks: Celebrity endorsements and viral content can be positive, but they also attract scrutiny. Make sure you’re watching compliance and advertising risk for consumer brands.

Bottom Line

• Ohio’s disbursement of cannabis tax revenue is a near-term positive for local political support and signals operational stability for operators in permissive jurisdictions.
• Record sales in Arkansas show the medical channel still has upside and that state markets can grow year over year, supporting top-line cases for producers and retailers.
• Bipartisan federal moves on CBD and hemp regulation increase the odds of broader market access, but rescheduling language remains ambiguous and timing is uncertain.
• Mainstream cultural moments are helping normalize cannabis, which can expand demand, but you should focus on companies that can convert awareness into regulated distribution and sales.
• Stay selective and time your exposure around policy clarity, earnings updates, and state-level sales reports; the sector is building momentum, but execution matters.

FAQ Section

Q: Will Ohio’s revenue distribution mean faster market growth for local cannabis businesses? A: Not directly, but it reduces political risk and may lead to local investments that support retail and infrastructure, which can indirectly help operators.

Q: Does federal rescheduling automatically open banking and interstate commerce? A: No, rescheduling is a legal step but not a full fix; banking and interstate commerce also rely on implementing regulations and legislative or administrative follow-through.

Q: Should I buy cannabis ETFs now because of these headlines? A: Headlines improve the backdrop, but you should assess each ETF and company fundamentals, watch for upcoming earnings, and consider policy timing before adding exposure.